DZ3402A1 - Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement - Google Patents

Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement

Info

Publication number
DZ3402A1
DZ3402A1 DZ013402A DZ013402A DZ3402A1 DZ 3402 A1 DZ3402 A1 DZ 3402A1 DZ 013402 A DZ013402 A DZ 013402A DZ 013402 A DZ013402 A DZ 013402A DZ 3402 A1 DZ3402 A1 DZ 3402A1
Authority
DZ
Algeria
Prior art keywords
treatment
cyclopentanoindoles
methods
same
compositions containing
Prior art date
Application number
DZ013402A
Other languages
English (en)
Inventor
Marc Labelle
Claudio Sturino
Bruno Roy
Carl Berthelette
Michael Boyd
Nicolas Lachance
John Scheigetz
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Application granted granted Critical
Publication of DZ3402A1 publication Critical patent/DZ3402A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/38—TPC being performed in particular situations
    • H04W52/46—TPC being performed in particular situations in multi hop networks, e.g. wireless relay networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B17/00—Monitoring; Testing
    • H04B17/30—Monitoring; Testing of propagation channels
    • H04B17/309—Measuring or estimating channel quality parameters
    • H04B17/318—Received signal strength
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W48/00—Access restriction; Network selection; Access point selection
    • H04W48/02—Access restriction performed under specific conditions
    • H04W48/04—Access restriction performed under specific conditions based on user or terminal location or mobility data, e.g. moving direction, speed
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/06—TPC algorithms
    • H04W52/14—Separate analysis of uplink or downlink
    • H04W52/146—Uplink power control
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/28—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non transmission
    • H04W52/288—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non transmission taking into account the usage mode, e.g. hands-free, data transmission, telephone
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W48/00—Access restriction; Network selection; Access point selection
    • H04W48/20—Selecting an access point
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H04W52/245—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters taking into account received signal strength
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H04W52/247—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters where the output power of a terminal is based on a path parameter sent by another terminal

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Quality & Reliability (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Computer Security & Cryptography (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Steroid Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
DZ013402A 2000-07-25 2001-07-23 Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement DZ3402A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22068300P 2000-07-25 2000-07-25

Publications (1)

Publication Number Publication Date
DZ3402A1 true DZ3402A1 (fr) 2002-01-31

Family

ID=22824535

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013402A DZ3402A1 (fr) 2000-07-25 2001-07-23 Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement

Country Status (34)

Country Link
US (1) US6410583B1 (fr)
EP (1) EP1305286B1 (fr)
JP (1) JP4119745B2 (fr)
KR (1) KR100746814B1 (fr)
CN (1) CN1214007C (fr)
AT (1) ATE284388T1 (fr)
AU (2) AU2001277430B2 (fr)
BG (1) BG66084B1 (fr)
BR (1) BR0112756A (fr)
CA (1) CA2416867C (fr)
CZ (1) CZ2003236A3 (fr)
DE (1) DE60107687T2 (fr)
DK (1) DK1305286T3 (fr)
DZ (1) DZ3402A1 (fr)
EA (1) EA006765B1 (fr)
EC (1) ECSP034428A (fr)
EE (1) EE05287B1 (fr)
ES (1) ES2231526T3 (fr)
GE (1) GEP20053595B (fr)
HK (1) HK1058934A1 (fr)
HR (1) HRP20021039B1 (fr)
HU (1) HUP0301745A3 (fr)
IL (2) IL153406A0 (fr)
IS (1) IS2170B (fr)
MX (1) MXPA03000710A (fr)
NO (1) NO325011B1 (fr)
NZ (1) NZ523106A (fr)
PL (1) PL207342B1 (fr)
PT (1) PT1305286E (fr)
RS (1) RS50491B (fr)
SK (1) SK287507B6 (fr)
UA (1) UA73787C2 (fr)
WO (1) WO2002008186A2 (fr)
ZA (1) ZA200300554B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217725B2 (en) * 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
US7273883B2 (en) * 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
US6916922B2 (en) 2000-11-03 2005-07-12 Wyeth Process for the preparation of 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta [B] [1,4] diazepino- [6,7,1-hi] indole derivatives
US6759405B2 (en) 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031196A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de ciclopenta (b) (1,4)-diazepino (6,7,1-hi) indoles y derivados
AR031197A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta(b) diazepino(6,7,1-hi)indol
AR031199A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
US6777407B2 (en) 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
DE60106641T2 (de) * 2000-11-03 2005-12-01 Wyeth Cyclopenta[b][1,4] diazepino[6,7,1-hi]indole als 5ht2c antagonisten
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200400963A (en) 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
TW200400818A (en) 2002-05-21 2004-01-16 Wyeth Corp Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
US20070054951A1 (en) * 2003-05-20 2007-03-08 Lianhai Li Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
AU2004247285A1 (en) * 2003-06-12 2004-12-23 Merck Frosst Canada Ltd Cycloalkanepyrrolopyridines as DP receptor antagonists
JP4769718B2 (ja) * 2003-08-07 2011-09-07 メルク シャープ エンド ドーム リミテッド アルツハイマー病及び関連症状の治療
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
EP1768674A1 (fr) 2004-07-16 2007-04-04 ProteoSys AG Antagonistes muscariniques avec activite modulatrice parp et sir en tant qu'agents cytoprotecteurs
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US20090054423A1 (en) * 2005-04-13 2009-02-26 Imbriglio Jason E Niacin receptor agonists, compositions containing such compounds and methods of treatment
US7902177B2 (en) 2005-05-02 2011-03-08 Wandzel Richard A Treatment of congestion using steroids and adrenergics
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
HUE030424T2 (en) * 2008-07-23 2017-05-29 Arena Pharm Inc Substituted 1,2,3,4-tetrahydrocyclopenta [b] indol-3-ylacetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
ES2583630T3 (es) * 2008-08-27 2016-09-21 Arena Pharmaceuticals, Inc. Derivados de ácido tricíclico sustituido como agonistas del receptor S1P1 útiles en el tratamiento de trastornos autoinmunes e inflamatorios
US8507473B2 (en) 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
WO2010034110A1 (fr) * 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Dérivés de bêta-carboline sulfonylurée en tant qu’antagonistes du récepteur d’ep4
WO2010081823A1 (fr) 2009-01-13 2010-07-22 Proteosys Ag Pirenzépine au titre d'agent otoprotecteur
MX2012004796A (es) 2009-10-26 2012-06-08 Bayer Cropscience Ag Nueva forma solida de 4-[[(6-cloropiridin-3-il)metil]-(2,2-difluor oetil)amino]furan-2(5h)-ona.
CN103221391B (zh) 2010-01-27 2018-07-06 艾尼纳制药公司 (R)-2-(7-(4-环戊基-3-(三氟甲基)苄基氧基)-1,2,3,4-四氢环戊二烯并[b]吲哚-3-基)乙酸及其盐的制备方法
JP2013521301A (ja) 2010-03-03 2013-06-10 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体修飾物質およびその結晶形の調製のためのプロセス
WO2014066568A1 (fr) 2012-10-24 2014-05-01 Winthrop-University Hospital Biomarqueur non invasif permettant d'identifier des sujets risquant un accouchement avant terme
CN107405332A (zh) 2015-01-06 2017-11-28 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
JP6770522B2 (ja) * 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
US10301262B2 (en) 2015-06-22 2019-05-28 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
EP3582772A1 (fr) 2017-02-16 2019-12-25 Arena Pharmaceuticals, Inc. Composés et méthodes de traitement de l'angiocholite biliaire primitive
MA47503A (fr) 2017-02-16 2021-04-21 Arena Pharm Inc Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
CA3075688A1 (fr) 2017-09-13 2019-03-21 Progenity, Inc. Biomarqueurs de pre-eclampsie ainsi que systemes et procedes associes
US11279656B2 (en) * 2017-10-27 2022-03-22 Applied Materials, Inc. Nanopowders, nanoceramic materials and methods of making and use thereof
EP3847158A1 (fr) 2018-09-06 2021-07-14 Arena Pharmaceuticals, Inc. Composés utiles dans le traitement de troubles auto-immuns et inflammatoires
EP4070113A4 (fr) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié
CN115260173A (zh) * 2021-04-30 2022-11-01 厦门宝太生物科技股份有限公司 环戊烷并吲哚类支链酸衍生物及其制备方法和应用
CN116854622A (zh) * 2023-07-10 2023-10-10 青岛科技大学 一种多取代的2,4-二氢环戊二烯并[b]吲哚类化合物的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (fr) 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
DE3768097D1 (de) 1986-01-23 1991-04-04 Merck Frosst Canada Inc Tetrahydrocarbazol-1-alkansaeuren.
US5221678A (en) 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
GB9101375D0 (en) 1991-01-22 1991-03-06 Erba Carlo Spa N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
DK0837052T3 (da) * 1995-06-21 2007-01-02 Shionogi & Co Bicykliske aminoderivater og PGD2-antagonist indeholdende disse
HU226458B1 (en) * 1996-12-13 2008-12-29 Shionogi & Co Benzothiophenecarboxamide derivatives, pharmaceutical compositions thereof and intermediates
ATE295183T1 (de) * 1998-06-03 2005-05-15 Shionogi & Co Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten

Also Published As

Publication number Publication date
EE05287B1 (et) 2010-04-15
US6410583B1 (en) 2002-06-25
ES2231526T3 (es) 2005-05-16
ECSP034428A (es) 2003-03-10
CA2416867A1 (fr) 2002-01-31
DE60107687D1 (de) 2005-01-13
EP1305286B1 (fr) 2004-12-08
CA2416867C (fr) 2008-03-25
KR100746814B1 (ko) 2007-08-06
BG107438A (bg) 2003-09-30
MXPA03000710A (es) 2003-06-04
NO20030374D0 (no) 2003-01-24
EP1305286A2 (fr) 2003-05-02
HRP20021039A2 (en) 2004-10-31
CN1214007C (zh) 2005-08-10
BR0112756A (pt) 2003-06-24
HUP0301745A2 (hu) 2003-09-29
ZA200300554B (en) 2004-04-23
ATE284388T1 (de) 2004-12-15
KR20030024810A (ko) 2003-03-26
CN1443165A (zh) 2003-09-17
IS2170B (is) 2006-11-15
NO20030374L (no) 2003-01-24
WO2002008186A3 (fr) 2002-03-21
IL153406A0 (en) 2003-07-06
HK1058934A1 (en) 2004-06-11
HRP20021039B1 (en) 2011-03-31
NO325011B1 (no) 2008-01-14
PT1305286E (pt) 2005-04-29
UA73787C2 (en) 2005-09-15
CZ2003236A3 (cs) 2003-05-14
SK287507B6 (sk) 2010-12-07
WO2002008186A2 (fr) 2002-01-31
NZ523106A (en) 2005-01-28
YU97902A (sh) 2006-05-25
RS50491B (sr) 2010-03-02
AU7743001A (en) 2002-02-05
IL153406A (en) 2008-03-20
EA006765B1 (ru) 2006-04-28
IS6655A (is) 2002-12-12
DE60107687T2 (de) 2005-12-01
AU2001277430B2 (en) 2006-05-25
EA200300171A1 (ru) 2003-06-26
DK1305286T3 (da) 2005-03-14
GEP20053595B (en) 2005-08-10
EE200300033A (et) 2004-10-15
JP2004504380A (ja) 2004-02-12
PL207342B1 (pl) 2010-12-31
HUP0301745A3 (en) 2010-03-29
JP4119745B2 (ja) 2008-07-16
SK932003A3 (en) 2003-06-03
BG66084B1 (bg) 2011-03-31
PL363168A1 (en) 2004-11-15

Similar Documents

Publication Publication Date Title
DZ3402A1 (fr) Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement
JO2481B1 (en) Silo cano-indol compounds have fluoride substitution and formulations containing such compounds and their treatment methods
BR0113286B1 (pt) pirazàis substituÍdos e composiÇço farmacÊutica compreendendo os mesmos.
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
DZ3265A1 (fr) Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2
IS4695A (is) (Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem sýklóoxýgenasa-2 tálmar
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
CY1105039T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ ΒΕΝΖΟ[b]ΑΖΕΠΙΝ-2-ΟΝΗΣ
ES2243579T3 (es) Derivados de pirazolopirideno.
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
YU39201A (sh) Upotreba 1-arilpirazola za pripremanje oralnog sredstva za suzbijanje parazita
SE9801494D0 (sv) Novel use
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
SE0001631D0 (sv) New use
CO5150221A1 (es) Nuevas 3-fenoxi- y 3-fenilalquiloxi-2-fenil-propilaminas sustituidas
SE0002045D0 (sv) New use
MXPA03003466A (es) Derivados de piranosido.
CR20120385A (es) Nuevos pirrolocarbazoles fusionados (divisional exp. 8519)